CDKN2A and neoplasm: The largest study was a pan-tumor study of CDKN2A and MTAP expression as a surrogate for 9p21.3 heterozygous or homozygous deletion, which confirmed our earlier HNSC/TME findings (3), specifically showing that 9p21.3 loss in HPV– HNSC was associated with immune-cold, CD8 T-cell depleted TME.